The Different Strategies for the Radiolabeling of [<sup>211</sup>At]-Astatinated Radiopharmaceuticals
Astatine-211 (<sup>211</sup>At) has emerged as a promising radionuclide for targeted alpha therapy of cancer by virtue of its favorable nuclear properties. However, the limited in vivo stability of <sup>211</sup>At-labeled radiopharmaceuticals remains a major challenge. This...
Saved in:
Main Authors: | Jie Gao (Author), Mei Li (Author), Jingjing Yin (Author), Mengya Liu (Author), Hongliang Wang (Author), Jin Du (Author), Jianguo Li (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2024-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Astatine-211 radiolabelling chemistry: from basics to advanced biological applications
by: Maarten Vanermen, et al.
Published: (2024) -
Pretargeted Alpha Therapy of Disseminated Cancer Combining Click Chemistry and Astatine-211
by: Chiara Timperanza, et al.
Published: (2023) -
Synthesis and Preclinical Evaluation of Radiolabeled [<sup>103</sup>Ru]BOLD-100
by: Barbara Happl, et al.
Published: (2023) -
Astatine-211-Labeled Gold Nanoparticles for Targeted Alpha-Particle Therapy via Intravenous Injection
by: Xuhao Huang, et al.
Published: (2022) -
[<sup>68</sup>Ga]Ga-DOTA-TOC: The First FDA-Approved <sup>68</sup>Ga-Radiopharmaceutical for PET Imaging
by: Ute Hennrich, et al.
Published: (2020)